SpringerLink
Log in

Psoriatic Arthritis Under a Proteomic Spotlight: Application of Novel Technologies to Advance Diagnosis and Management

  • Psoriatic Arthritis (O FitzGerald and P Helliwell, Section Editors)
  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

Psoriatic arthritis is a form of inflammatory arthritis that is frequently associated with psoriasis. Individuals with this disease present with heterogeneous clinical manifestations, making it challenging to diagnose and select optimal treatment strategies. Perhaps, not unsurprisingly, there are currently no molecular diagnostic or prognostic tests to confirm if a patient has the disease or predict how they may respond to therapy. Instead, a range of classification criteria have been developed, and the experience of the treating clinician is heavily relied upon. It is therefore widely accepted that there is a significant and as yet unmet need for effective molecular markers in psoriatic arthritis. Protein mediators drive disease pathogenesis and, therefore, represent logical potential biomarkers. Indeed, significant advances have recently been made by the introduction of multiplexed protein biomarker tests for monitoring disease activity in rheumatoid arthritis. At the same time, recent advances in proteomics have enhanced the capabilities for the detection and discovery of protein biomarkers. These advances offer renewed opportunities for the development of multi-protein biomarker signatures to support clinical decision-making in the diagnosis, prognosis and treatment of psoriatic arthritis. This review summarises the pathogenesis of psoriatic arthritis, highlighting specific areas of unmet clinical need. Furthermore, it seeks to illustrate how the latest developments in proteomic technologies could be used to enhance our understanding of the molecular pathology of psoriatic arthritis and improve clinical outcomes and quality of life for patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (France)

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Hirsch JHK, Burlingame AL, Matthey MA. Proteomics: current techniques and potential applications to lung disease. Am J Physiol. 2004;28(7):17–23.

    Google Scholar 

  2. Whiteaker JR, Halusa GN, Hoofnagle AN, Sharma V, MacLean B, Yan P, et al. CPTAC assay Portal: a repository of targeted proteomic assays. Nat Methods. 2014;7:703–4.

    Google Scholar 

  3. Yates JR, Ruse CI, Nakorchevsky A. Proteomics by mass spectrometry: approaches, advances, and applications. Annu Rev Biomed Eng. 2009;11:49–79.

    CAS  PubMed  Google Scholar 

  4. Helliwell PS, FitzGerald O, Fransen J, Gladman DD, Kreuger GG, Callis-Duffin K, et al. The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). Ann Rheum Dis. 2013;72(6):986–91.

    PubMed  Google Scholar 

  5. LaFramboise WA, Dhir R, Kelly LA, Petrosko P, Krill-Burger JM, Sciulli CM, et al. Serum protein profiles predict coronary artery disease in symptomatic patients referred for coronary angiography. BMC Med. 2012;10:157.

    PubMed Central  CAS  PubMed  Google Scholar 

  6. Curtis JR, van der Helm-van Mil AH, Knevel R, Huizinga TW, Haney DJ, Shen Y, et al. Validation of a novel multibiomarker test to assess rheumatoid arthritis disease activity. Arthritis Care Res. 2012;64(12):1794–803.

    Google Scholar 

  7. Eastman PS, Manning WC, Qureshi F, Haney D, Cavet G, Alexander C, et al. Characterization of a multiplex, 12-biomarker test for rheumatoid arthritis. J Pharm Biomed Anal. 2012;70:415–24.

    CAS  PubMed  Google Scholar 

  8. Punzi L, Podswiadek M, Sfriso P, Oliviero F, Fiocco U, Todesco S. Pathogenetic and clinical rationale for TNF-blocking therapy in psoriatic arthritis. Autoimmun Rev. 2007;6:524–8.

    CAS  PubMed  Google Scholar 

  9. Duarte GV, Faillace C. Freire de Carvalho J: Psoriatic arthritis. Best Pract Res Clin Rheumatol. 2012;26:147–56.

    PubMed  Google Scholar 

  10. Moll JMWV. Psoriatic Arthritis. Semin Arthritis Rheum. 1973;3(1):55–78.

    CAS  PubMed  Google Scholar 

  11. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54:2665–73.

    PubMed  Google Scholar 

  12. Alamanos Y, Voulgari PV. Drosos Aa: Incidence and prevalence of psoriatic arthritis: a systematic review. J Rheumatol. 2008;35:1354–8.

    PubMed  Google Scholar 

  13. Leung YY, Tam LS, Ho KW, Lau WM, Li TK-Y, Zhu TY, et al. Evaluation of the CASPAR criteria for psoriatic arthritis in the Chinese population. Rheumatology (Oxford, England). 2010;49:112–5.

    Google Scholar 

  14. Coates LC, Conaghan PG, Emery P, Green MJ, Ibrahim G, MacIver H, et al. Sensitivity and specificity of the classification of psoriatic arthritis criteria in early psoriatic arthritis. Arthritis Rheum. 2012;64:3150–5.

    PubMed  Google Scholar 

  15. Eder L, Chandran V, Shen H, Cook RJ, Shanmugarajah S, Rosen CF, et al. Incidence of arthritis in a prospective cohort of psoriasis patients. Arthritis Care Res. 2011;63:619–22.

    Google Scholar 

  16. Ogdie A, Langan S, Love T, Haynes K, Shin D, Seminara N, et al. Prevalence and treatment patterns of psoriatic arthritis in the UK. Rheumatology (Oxford, England). 2013;52:568–75.

    Google Scholar 

  17. Winchester R. Epidemiology, genetics and management of psoriatic arthritis 2013: focus on developments of who develops the disease, its clinical features, and emerging treatment options. Psoriasis: Targets Ther. 2013;11.

  18. Reich K, Krüger K, Mössner R, Augustin M. Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis. Br j dermatol. 2009;160:1040–7.

    CAS  PubMed  Google Scholar 

  19. Yang Q, Qu L, Tian H, Hu Y, Peng J, Yu X, et al. Prevalence and characteristics of psoriatic arthritis in Chinese patients with psoriasis. J Eur Acad Dermatol Venereol: JEADV. 2011;25:1409–14.

    CAS  PubMed  Google Scholar 

  20. Y-y L, L-s T, Li EK. The Perspective on Psoriatic Arthritis in Asia. Curr Rheumatol Rep. 2011;369–375.

  21. Costello PJ, Winchester RJ, Curran SA, Peterson KS, Kane DJ, Bresnihan B, et al. Psoriatic Arthritis Joint Fluids Are Characterized by CD8 and CD4 T Cell Clonal Expansions that Appear Antigen Driven. J Immunol. 2001;166:2878–86.

    CAS  PubMed  Google Scholar 

  22. Borgato LPA, Beri R, Codella O, Frigo A, Simeoni S, Pacor ML, et al. The T cell receptor repertoire in psoriatic synovitis is restricted and T lymphocytes expressing the same TCR are present in joint and skin lesions. J Rheumatol. 2002;29:1914–9.

    CAS  PubMed  Google Scholar 

  23. Veale DJ, Ritchlin C, FitzGerald O. Immunopathology of psoriasis and psoriatic arthritis. Ann Rheum Dis. 2005;64 Suppl 2:ii26–9.

    PubMed Central  PubMed  Google Scholar 

  24. Menon B, Gullick NJ, Walter GJ, Rajasekhar M, Garrood T, Evans HG, et al. Interleukin-17+CD8+ T cells are enriched in the joints of patients with psoriatic arthritis and correlate with disease activity and joint damage progression. Arthritis Rheumatol (Hoboken, NJ). 2014;66:1272–81.

    CAS  Google Scholar 

  25. van Kuijk AWR, Reinders-Blankert P, Smeets TJM, Dijkmans BC, Tak PP. Detailed analysis of the cell infiltrate and the expression of mediators of synovial inflammation and joint destruction in the synovium of patients with psoriatic arthritis: implications for treatment. Ann Rheum Dis. 2006;65:1551–7.

    PubMed Central  PubMed  Google Scholar 

  26. Lande R, Giacomini E, Serafini B, Rosicarelli B, Sebastiani GD, Minisola G, et al. Characterization and Recruitment of Plasmacytoid Dendritic Cells in Synovial Fluid and Tissue of Patients with Chronic Inflammatory Arthritis. J Immunol. 2004;173:2815–24.

    CAS  PubMed  Google Scholar 

  27. Veale DJ, FitzGerald O. Psoriatic arthritis-pathogenesis and epidemiology. Clin Exp Rheumatol. 2002;20:S27–33.

    CAS  PubMed  Google Scholar 

  28. van Kuijk AW, Tak PP. Synovitis in psoriatic arthritis: immunohistochemistry, comparisons with rheumatoid arthritis, and effects of therapy. Curr Rheumatol Rep. 2011;13(4):353–9.

    PubMed Central  CAS  PubMed  Google Scholar 

  29. Chimenti MS, Ballanti E, Perricone C, Cipriani P, Giacomelli R, Perricone R. Immunomodulation in psoriatic arthritis: focus on cellular and molecular pathways. Autoimmun Rev. 2013;12:599–606.

    CAS  PubMed  Google Scholar 

  30. Gladman DD. Clinical, radiological, and functional assessment in psoriatic arthritis: is it different from other inflammatory joint diseases? Ann Rheum Dis. 2006;65 Suppl 3:iii22–4.

    PubMed Central  PubMed  Google Scholar 

  31. Yy L, Ls T, Ew K, Ek L. Psoriatic arthritis as a distinct disease entity. J Postgrad Med. 2007;53:63–72.

    Google Scholar 

  32. Nash P, Clegg DO. Psoriatic arthritis therapy: NSAIDs and traditional DMARDs. Ann Rheum Dis. 2005;64 Suppl 2:ii74–7.

    PubMed Central  CAS  PubMed  Google Scholar 

  33. Gossec L, Smolen JS, Gaujoux-Viala C, Ash Z, Marzo-Ortega H, van der Heijde D, et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis. 2012;71(1):4–12.

    CAS  PubMed  Google Scholar 

  34. Lie E, van der Heijde D, Uhlig T, Heiberg MS, Koldingsnes W, Rødevand E, et al. Effectiveness and retention rates of methotrexate in psoriatic arthritis in comparison with methotrexate-treated patients with rheumatoid arthritis. Ann Rheum Dis. 2010;69:671–6.

    CAS  PubMed  Google Scholar 

  35. Gladman DD. Adalimumab, etanercept and infliximab are equally effective treatments for patients with psoriatic arthritis. Nautre Clin Pract Rheumatol. 2008;4(10):510–1.

    CAS  Google Scholar 

  36. Mease PJ, Fleischmann R, Deodhar AA, Wollenhaupt J, Khraishi M, Kielar D, et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis. 2014;73(1):48–55.

    PubMed Central  CAS  PubMed  Google Scholar 

  37. Girolomoni G, Mrowietz U, Paul C. Psoriasis: rationale for targeting interleukin-17. Br J Dermatol. 2012;167(4):717–24.

    CAS  PubMed  Google Scholar 

  38. Gaffen SL, Jain R, Garg AV, Cua DJ. The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing. Nat Rev Immunol. 2014;14(9):585–600.

    CAS  PubMed  Google Scholar 

  39. Novelli L, Chimenti MS, Chiricozzi A, Perricone R. The new era for the treatment of psoriasis and psoriatic arthritis: perspectives and validated strategies. Autoimmun Rev. 2014;13:64–9.

    CAS  PubMed  Google Scholar 

  40. Gottlieb A, Menter A, Mendelsohn A, Shen Y-K, Li S, Guzzo C, et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet. 2009;373:633–40.

    CAS  PubMed  Google Scholar 

  41. McInnes IB, Sieper J, Braun J, Emery P, van der Heijde D, Isaacs JD, et al. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. Ann Rheum Dis. 2014;73:349–56.

    CAS  PubMed  Google Scholar 

  42. Leonardi C, Matheson R, Zachariae C, Cameron G, Li L, Edson-Heredia E, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med. 2012;366:1190–9.

    CAS  PubMed  Google Scholar 

  43. Helliwell P, Taylor W. Classification and diagnostic criteria orpsoriatic arthritis. Ann Rheum Dis. 2005;64:ii3–8.

    PubMed Central  PubMed  Google Scholar 

  44. Helliwell PS, Fitzgerald O, Mease PJ, Gladman DD. GRAPPA Responder Index Project (GRACE): a report from the GRAPPA 2011 annual meeting. J Rheumatol. 2012;39(11):2196–7.

    PubMed  Google Scholar 

  45. Ortea I, Pascoal A, Canas B, Gallardo JM, Barros-Velazquez J, Calo-Mata P. Food authentication of commercially-relevant shrimp and prawn species: from classical methods to Foodomics. Electrophoresis. 2012;33(15):2201–11.

    CAS  PubMed  Google Scholar 

  46. Bowes J, Barton A. The genetics of psoriatic arthritis: lessons from genome-wide association studies. Discov Med. 2010;10(52):177–83.

    PubMed  Google Scholar 

  47. Wetie AG, Woods AG, Darie CC. Mass spectrometric analysis of posttranslational modifications (PTMs) and protein-protein interactions (PPIs). Adv Exp Med Biol. 2014;806:205–35.

    CAS  Google Scholar 

  48. Lories RJU, Derese I, de Vlam K. Mitogen-activated kinases in psoriatic arthritis: differences in activation and distinct regulation by etanercept therapy. Arthritis Res Ther. 2005;7 Suppl 1:88.

    Google Scholar 

  49. Mavropoulos A, Rigopoulou EI, Liaskos C, Bogdanos DP, Sakkas LI. The role of p38 MAPK in the aetiopathogenesis of psoriasis and psoriatic arthritis. Clin Develop Immunol. 2013;2013:569751.

    Google Scholar 

  50. Lizzul PF, Aphale A, Malaviya R, Sun Y, Masud S, Dombrovskiy V, et al. Differential expression of phosphorylated NF-kappaB/RelA in normal and psoriatic epidermis and downregulation of NF-kappaB in response to treatment with etanercept. J Invest Dermatol. 2005;124(6):1275–83.

    CAS  PubMed  Google Scholar 

  51. Raychaudhuri SK, Raychaudhuri SP. mTOR Signaling Cascade in Psoriatic Disease: Double Kinase mTOR Inhibitor a Novel Therapeutic Target. Ind J Dermatol. 2014;59(1):67–70.

    Google Scholar 

  52. Doyle MS, Collins ES, FitzGerald OM, Pennington SR. New insights into the role of interllukin-17 receptor adaptor protein Act1 in psoriatic arthrtisi. Arthritis Res Ther. 2012;14:226.

    PubMed Central  CAS  PubMed  Google Scholar 

  53. Bensimon A, Heck AJ, Aebersold R. Mass spectrometry-based proteomics and network biology. Annu Rev Biochem. 2012;81:379–405.

    CAS  PubMed  Google Scholar 

  54. Cox J, Mann M. Quantitative, high-resolution proteomics for data-driven systems biology. Annu Rev Biochem. 2011;80:273–99.

    CAS  PubMed  Google Scholar 

  55. Gstaiger M, Aebersold R. Applying mass spectrometry-based proteomics to genetics, genomics and network biology. Nat Rev Genet. 2009;10(9):617–27.

    CAS  PubMed  Google Scholar 

  56. Kim MS, Pinto SM, Getnet D, Nirujogi RS, Manda SS, Chaerkady R, et al. A draft map of the human proteome. Nature. 2014;509(7502):575–81.

    PubMed Central  CAS  PubMed  Google Scholar 

  57. Wilhelm M, Schlegl J, Hahne H, Moghaddas Gholami A, Lieberenz M, Savitski MM, et al. Mass-spectrometry-based draft of the human proteome. Nature. 2014;509(7502):582–7.

    CAS  PubMed  Google Scholar 

  58. Uhlen M, Bjorling E, Agaton C, Szigyarto CA, Amini B, Andersen E, et al. A human protein atlas for normal and cancer tissues based on antibody proteomics. Mol Cell Proteomics: MCP. 2005;4(12):1920–32.

    CAS  PubMed  Google Scholar 

  59. Uhlen M, Fagerberg L, Hallstrom BM, Lindskog C, Oksvold P, Mardinoglu A, et al. Proteomics. Tissue-based map of the human proteome. Science. 2015;347(6220):1260419.

    PubMed  Google Scholar 

  60. Uhlen M, Oksvold P, Fagerberg L, Lundberg E, Jonasson K, Forsberg M, et al. Towards a knowledge-based Human Protein Atlas. Nat Biotechnol. 2010;28(12):1248–50.

    CAS  PubMed  Google Scholar 

  61. Guerrero C, Tagwerker C, Kaiser P, Huang L. An integrated mass spectrometrybased proteomic approach: quantitative analysis of tandem affinity-purified in vivo cross-linked protein complexes (QTAX) to decipher the 26 S proteasomeinteracting network. MolCell Proteomics: MCP. 2006;5(2):366–78.

    CAS  PubMed  Google Scholar 

  62. Gygi SP, Rist B, Gerber SA, Turecek F, Gelb MH, Aebersold R. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat Biotechnol. 1999;17(10):994–9.

    CAS  PubMed  Google Scholar 

  63. Jiang X, Coffino P, Li X. Development of a method for screening short-lived proteins using green fluorescent protein. Genome Biol. 2004;5(10):R81.

    PubMed Central  PubMed  Google Scholar 

  64. Wang X, Chen CF, Baker PR, Chen PL, Kaiser P, Huang L. Mass spectrometric characterization of the affinity-purified human 26S proteasome complex. Biochemistry. 2007;46(11):3553–65.

    CAS  PubMed  Google Scholar 

  65. Dixon DP, Skipsey M, Grundy NM, Edwards R. Stress-induced protein Sglutathionylation in Arabidopsis. Plant Physiol. 2005;138(4):2233–44.

    PubMed Central  CAS  PubMed  Google Scholar 

  66. Kusch H, Engelmann S, Albrecht D, Morschhauser J, Hecker M. Proteomic analysis of the oxidative stress response in Candida albicans. Proteomics. 2007;7(5):686–97.

    CAS  PubMed  Google Scholar 

  67. **ao GG, Recker RR, Deng HW. Recent advances in proteomics and cancer biomarker discovery. Clin Med Oncol. 2008;2:63–72.

    PubMed Central  CAS  PubMed  Google Scholar 

  68. Graves PR, Haystead TA. Molecular biologist's guide to proteomics. Microbiol Mol Biol Rev: MMBR. 2002;66(1):39–63. table of contents.

    PubMed Central  CAS  PubMed  Google Scholar 

  69. Aggarwal K, Choe LH, Lee KH. Shotgun proteomics using the iTRAQ isobaric tags. Brief Funct Genomics Proteomics. 2006;5(2):112–20.

    CAS  Google Scholar 

  70. Maurya P, Meleady P, Dowling P, Clynes M. Proteomic approaches for serum biomarker discovery in cancer. Anticancer Res. 2007;27(3A):1247–55.

    CAS  PubMed  Google Scholar 

  71. Ross PL, Huang YN, Marchese JN, Williamson B, Parker K, Hattan S, et al. Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol Cell Proteomics: MCP. 2004;3(12):1154–69.

    CAS  PubMed  Google Scholar 

  72. Gronborg M, Kristiansen TZ, Iwahori A, Chang R, Reddy R, Sato N, et al. Biomarker discovery from pancreatic cancer secretome using a differential proteomic approach. Mol Cell Proteomics: MCP. 2006;5(1):157–71.

    CAS  PubMed  Google Scholar 

  73. Guerrera IC, Keep NH, Godovac-Zimmermann J. Proteomics study reveals crosstalk between Rho guanidine nucleotide dissociation inhibitor 1 post-translational modifications in epidermal growth factor stimulated fibroblasts. J Proteome Res. 2007;6(7):2623–30.

    CAS  PubMed  Google Scholar 

  74. Bose R, Molina H, Patterson AS, Bitok JK, Periaswamy B, Bader JS, et al. Phosphoproteomic analysis of Her2/neu signaling and inhibition. Proc Natl Acad Sci U S A. 2006;103(26):9773–8.

    PubMed Central  CAS  PubMed  Google Scholar 

  75. Foster LJ, Rudich A, Talior I, Patel N, Huang X, Furtado LM, et al. Insulin-dependent interactions of proteins with GLUT4 revealed through stable isotope labeling by amino acids in cell culture (SILAC). J Proteome Res. 2006;5(1):64–75.

    CAS  PubMed  Google Scholar 

  76. Selbach M, Mann M. Protein interaction screening by quantitative immunoprecipitation combined with knockdown (QUICK). Nat Methods. 2006;3(12):981–3.

    CAS  PubMed  Google Scholar 

  77. Waanders LF, Hanke S, Mann M. Top-down quantitation and characterization of SILAC-labeled proteins. J Am Soc Mass Spectrom. 2007;18(11):2058–64.

    CAS  PubMed  Google Scholar 

  78. Liang X, Fonnum G, Hajivandi M, Stene T, Kjus NH, Ragnhildstveit E, et al. Quantitative comparison of IMAC and TiO2 surfaces used in the study of regulated, dynamic protein phosphorylation. J Am Soc Mass Spectrom. 2007;18(11):1932–44.

    CAS  PubMed  Google Scholar 

  79. Soufi B, Jers C, Hansen ME, Petranovic D, Mijakovic I. Insights from site-specific phosphoproteomics in bacteria. Biochim Biophys Acta. 2008;1784(1):186–92.

    CAS  PubMed  Google Scholar 

  80. **ao GG, Garg M, Lim S, Wong D, Go VL, Lee WN. Determination of protein synthesis in vivo using labeling from deuterated water and analysis of MALDITOF spectrum. J Appl Physiol. 2008;104(3):828–36.

    CAS  PubMed  Google Scholar 

  81. Megger DA, Bracht T, Meyer HE, Sitek B. Label-free quantification in clinical proteomics. Biochim Biophys Acta. 2013;1834(8):1581–90.

    CAS  PubMed  Google Scholar 

  82. Old WM, Meyer-Arendt K, Aveline-Wolf L, Pierce KG, Mendoza A, Sevinsky JR, et al. Comparison of label-free methods for quantifying human proteins by shotgun proteomics. Mol Cell Proteomics: MCP. 2005;4(10):1487–502.

    CAS  PubMed  Google Scholar 

  83. Liu J, Bell AW, Bergeron JJ, Yanofsky CM, Carrillo B, Beaudrie CE, et al. Methods for peptide identification by spectral comparison. Proteome Sci. 2007;5:3.

    PubMed Central  PubMed  Google Scholar 

  84. Chelius D, Bondarenko PV. Quantitative profiling of proteins in complex mixtures using liquid chromatography and mass spectrometry. J Proteome Res. 2002;1(4):317–23.

    CAS  PubMed  Google Scholar 

  85. Bantscheff M, Schirle M, Sweetman G, Rick J, Kuster B. Quantitative mass spectrometry in proteomics: a critical review. Anal Bioanal Chem. 2007;389(4):1017–31.

    CAS  PubMed  Google Scholar 

  86. Westermeier R, Marouga R. Protein detection methods in proteomics research. Biosci Rep. 2005;25(1–2):19–32.

    CAS  PubMed  Google Scholar 

  87. Eng JK, McCormack AL, Yates JR. An approach to correlate tandem mass spectral data of peptides with amino acid sequences in a protein database. J Am Soc Mass Spectrom. 1994;5(11):976–89.

    CAS  PubMed  Google Scholar 

  88. Geer LY, Markey SP, Kowalak JA, Wagner L, Xu M, Maynard DM, et al. Open mass spectrometry search algorithm. J Proteome Res. 2004;3(5):958–64.

    CAS  PubMed  Google Scholar 

  89. Perkins DN, Pappin DJ, Creasy DM, Cottrell JS. Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis. 1999;20(18):3551–67.

    CAS  PubMed  Google Scholar 

  90. Dancik V, Addona TA, Clauser KR, Vath JE, Pevzner PA. De novo peptide sequencing via tandem mass spectrometry. J Comput Biol: J Comput Mol Cell Biol. 1999;6(3–4):327–42.

    CAS  Google Scholar 

  91. Pitzer E, Masselot A, Colinge J. Assessing peptide de novo sequencing algorithms performance on large and diverse data sets. Proteomics. 2007;7(17):3051–4.

    CAS  PubMed  Google Scholar 

  92. Shevchenko A, Chernushevich I, Ens W, Standing KG, Thomson B, Wilm M, et al. Rapid 'de novo' peptide sequencing by a combination of nanoelectrospray, isotopic labeling and a quadrupole/time-of-flight mass spectrometer. Rapid Commun Mass Spectrom: RCM. 1997;11(9):1015–24.

    CAS  PubMed  Google Scholar 

  93. Craig R, Cortens JC, Fenyo D, Beavis RC. Using annotated peptide mass spectrum libraries for protein identification. J Proteome Res. 2006;5(8):1843–9.

    CAS  PubMed  Google Scholar 

  94. Frewen BE, Merrihew GE, Wu CC, Noble WS, MacCoss MJ. Analysis of peptide MS/MS spectra from large-scale proteomics experiments using spectrum libraries. Anal Chem. 2006;78(16):5678–84.

    CAS  PubMed  Google Scholar 

  95. Yates 3rd JR, Morgan SF, Gatlin CL, Griffin PR, Eng JK. Method to compare collision-induced dissociation spectra of peptides: potential for library searching and subtractive analysis. Anal Chem. 1998;70(17):3557–65.

    CAS  PubMed  Google Scholar 

  96. Buts K, Michielssens S, Hertog ML, Hayakawa E, Cordewener J, America AH, et al. Improving the identification rate of data independent label-free quantitative proteomics experiments on non-model crops: a case study on apple fruit. J Proteome. 2014;105:31–45.

    CAS  Google Scholar 

  97. Plumb RS, Johnson KA, Rainville P, Smith BW, Wilson ID, Castro-Perez JM, et al. UPLC/MS(E); a new approach for generating molecular fragment information for biomarker structure elucidation. Rapid Commun Mass Spectrom: RCM. 2006;20(13):1989–94.

    CAS  PubMed  Google Scholar 

  98. Vertommen A, Moller AL, Cordewener JH, Swennen R, Panis B, Finnie C, et al. A workflow for peptide-based proteomics in a poorly sequenced plant: a case study on the plasma membrane proteome of banana. J Proteome. 2011;74(8):1218–29.

    CAS  Google Scholar 

  99. Gillet LC, Navarro P, Tate S, Rost H, Selevsek N, Reiter L, et al. Targeted data extraction of the MS/MS spectra generated by data-independent acquisition: a new concept for consistent and accurate proteome analysis. Mol Cell Proteomics: MCP. 2012;11(6):O111.016717.

    PubMed Central  PubMed  Google Scholar 

  100. Egertson JD, Kuehn A, Merrihew GE, Bateman NW, MacLean BX, Ting YS, et al. Multiplexed MS/MS for improved data-independent acquisition. Nat Methods. 2013;10(8):744–6.

    CAS  PubMed  Google Scholar 

  101. Fan Y, Thompson JW, Dubois LG, Moseley MA, Wernegreen JJ. Proteomic analysis of an unculturable bacterial endosymbiont (Blochmannia) reveals high abundance of chaperonins and biosynthetic enzymes. J Proteome Res. 2013;12(2):704–18.

    PubMed Central  CAS  PubMed  Google Scholar 

  102. Elliott MH, Smith DS, Parker CE, Borchers C. Current trends in quantitative proteomics. J Mass Spectrom: JMS. 2009;44(12):1637–60.

    CAS  PubMed  Google Scholar 

  103. Lange V, Picotti P, Domon B, Aebersold R. Selected reaction monitoring for quantitative proteomics: a tutorial. Mol Syst Biol. 2008;4:222.

    PubMed Central  PubMed  Google Scholar 

  104. Gerber SA, Rush J, Stemman O, Kirschner MW, Gygi SP. Absolute quantification of proteins and phosphoproteins from cell lysates by tandem MS. Proc Natl Acad Sci U S A. 2003;100(12):6940–5.

    PubMed Central  CAS  PubMed  Google Scholar 

  105. Qian WJ, Jacobs JM, Liu T, Camp 2nd DG, Smith RD. Advances and challenges in liquid chromatography-mass spectrometry-based proteomics profiling for clinical applications. Mol Cell Proteom: MCP. 2006;5(10):1727–44.

    CAS  Google Scholar 

  106. Wasinger VC, Zeng M, Yau Y. Current status and advances in quantitative proteomic mass spectrometry. Int J Proteom. 2013;2013:180605.

    Google Scholar 

  107. Anderson L, Hunter CL. Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol Cell Proteom: MCP. 2006;5(4):573–88.

    CAS  Google Scholar 

  108. Huillet C, Adrait A, Lebert D, Picard G, Trauchessec M, Louwagie M, et al. Accurate quantification of cardiovascular biomarkers in serum using Protein Standard Absolute Quantification (PSAQ) and selected reaction monitoring. Mol Cell Proteom: MCP. 2012;11(2):M111.008235.

    Google Scholar 

  109. Keshishian H, Addona T, Burgess M, Kuhn E, Carr SA. Quantitative, multiplexed assays for low abundance proteins in plasma by targeted mass spectrometry and stable isotope dilution. Mol Cell Proteom: MCP. 2007;6(12):2212–29.

    CAS  Google Scholar 

  110. Keshishian H, Addona T, Burgess M, Mani DR, Shi X, Kuhn E, et al. Quantification of cardiovascular biomarkers in patient plasma by targeted mass spectrometry and stable isotope dilution. Mol Cell Proteom: MCP. 2009;8(10):2339–49.

    CAS  Google Scholar 

  111. Kirsch S, Widart J, Louette J, Focant JF, De Pauw E. Development of an absolute quantification method targeting growth hormone biomarkers using liquid chromatography coupled to isotope dilution mass spectrometry. J Chromatogr A. 2007;1153(1–2):300–6.

    CAS  PubMed  Google Scholar 

  112. Kuhn E, Addona T, Keshishian H, Burgess M, Mani DR, Lee RT, et al. Develo** multiplexed assays for troponin I and interleukin-33 in plasma by peptide immunoaffinity enrichment and targeted mass spectrometry. Clin Chem. 2009;55(6):1108–17.

    PubMed Central  CAS  PubMed  Google Scholar 

  113. Kuhn E, Wu J, Karl J, Liao H, Zolg W, Guild B. Quantification of C-reactive protein in the serum of patients with rheumatoid arthritis using multiple reaction monitoring mass spectrometry and 13C-labeled peptide standards. Proteomics. 2004;4(4):1175–86.

    CAS  PubMed  Google Scholar 

  114. McKay MJ, Sherman J, Laver MT, Baker MS, Clarke SJ, Molloy MP. The development of multiple reaction monitoring assays for liver-derived plasma proteins. Proteomics Clin Appl. 2007;1(12):1570–81.

    CAS  PubMed  Google Scholar 

  115. Picard G, Lebert D, Louwagie M, Adrait A, Huillet C, Vandenesch F, et al. PSAQ standards for accurate MS-based quantification of proteins: from the concept to biomedical applications. J Mass Spectrom: JMS. 2012;47(10):1353–63.

    CAS  PubMed  Google Scholar 

  116. Schmidt A, Kellermann J, Lottspeich F. A novel strategy for quantitative proteomics using isotope-coded protein labels. Proteomics. 2005;5(1):4–15.

    CAS  PubMed  Google Scholar 

  117. Stahl-Zeng J, Lange V, Ossola R, Eckhardt K, Krek W, Aebersold R, et al. High sensitivity detection of plasma proteins by multiple reaction monitoring of Nglycosites. Mol Cell Proteom: MCP. 2007;6(10):1809–17.

    CAS  Google Scholar 

  118. Zhang Y, Zhao C, Liu H, Hou H, Zhang H. Multiple metastasis-like bone lesions in scintigraphic imaging. J Biomed Biotechnol. 2012;2012:957364.

    PubMed Central  PubMed  Google Scholar 

  119. Titz B, Elamin A, Martin F, Schneider T, Dijon S, Ivanov NV, et al. Proteomics for systems toxicology. Comput Struct Biotechnol J. 2014;11(18):73–90.

    PubMed Central  PubMed  Google Scholar 

  120. S Ademowo BH, E Collins, C Rooney, U Fearon AWvK, P Tak, D M Gerlag, O FitzGerald, SR Pennington: Discovery and confirmation of a protein biomarker panel with poteinal to predict reponse to biological therapy in psoriatic arthritis. Ann Rheum Dis. 2014:1–8.

  121. Cretu D, Prassas I, Saraon P, Batruch I, Gandhi R, Diamandis EP, et al. Identification of psoriatic arthritis mediators in synovial fluid by quantitative mass spectrometry. Clin Proteom. 2014;11(1):27.

    Google Scholar 

  122. Balakrishnan L, Bhattacharjee M, Ahmad S, Nirujogi RS, Renuse S, Subbannayya Y, et al. Differential proteomic analysis of synovial fluid from rheumatoid arthritis and osteoarthritis patients. Clin Proteom. 2014;11(1):1.

    Google Scholar 

  123. Gibson DS, Finnegan S, Jordan G, Scaife C, Brockbank S, Curry J, et al. Stratification and monitoring of juvenile idiopathic arthritis patients by synovial proteome analysis. J Proteome Res. 2009;8(12):5601–9.

    CAS  PubMed  Google Scholar 

  124. Finnegan S, Robson J, Scaife C, McAllister C, Pennington SR, Gibson DS, et al. Synovial membrane protein expression differs between juvenile idiopathic arthritis subtypes in early disease. Arthritis Res Ther. 2014;16(1):R8.

    PubMed Central  PubMed  Google Scholar 

  125. Lau TY, Collins BC, Stone P, Tang N, Gallagher WM, Pennington SR. Absolute quantification of toxicological biomarkers by multiple reaction monitoring. Methods Mol Biol. 2011;691:417–27.

    CAS  PubMed  Google Scholar 

  126. Oe T, Ackermann BL, Inoue K, Berna MJ, Garner CO, Gelfanova V, et al. Quantitative analysis of amyloid beta peptides in cerebrospinal fluid of Alzheimer's disease patients by immunoaffinity purification and stable isotope dilution liquid chromatography/negative electrospray ionization tandem mass spectrometry. Rapid Commun Mass Spectrom: RCM. 2006;20(24):3723–35.

    CAS  PubMed  Google Scholar 

  127. Collins BC, Miller CA, Sposny A, Hewitt P, Wells M, Gallagher WM, et al. Development of a pharmaceutical hepatotoxicity biomarker panel using a discovery to targeted proteomics approach. Mol Cell Proteom: MCP. 2012;11(8):394–410.

    Google Scholar 

  128. Morrissey B, O'Shea C, Armstrong J, Rooney C, Staunton L, Sheehan M, et al. Development of a label-free LC-MS/MS strategy to approach the identification of candidate protein biomarkers of disease recurrence in prostate cancer patients in a clinical trial of combined hormone and radiation therapy. Proteomics Clin Appl. 2013;7(5–6):316–26.

    CAS  PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Aisha Q. Butt, Angela McArdle, David S. Gibson and Stephen R. Pennington declare no conflicts of interest. Oliver FitzGerald declares the receipt of research grant support from Pfizer, Abbott, Roche, MSD, Amgen and UCB.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Author notes

    Authors and Affiliations

    1. School of Medicine and Medical Science, UCD Conway Institute, University College Dublin, Belfield, Dublin 4, Ireland

      Aisha Q. Butt, Angela McArdle, Oliver FitzGerald & Stephen R. Pennington

    2. Northern Ireland Centre for Stratified Medicine, University of Ulster, C-TRIC, Glenshane Road, Londonderry, BT47 6SB, UK

      David S. Gibson

    3. Department of Rheumatology, St. Vincent’s University Hospital, Elm Park, Dublin 4, Ireland

      Oliver FitzGerald

    Authors
    1. Aisha Q. Butt
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. Angela McArdle
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. David S. Gibson
      View author publications

      You can also search for this author in PubMed Google Scholar

    4. Oliver FitzGerald
      View author publications

      You can also search for this author in PubMed Google Scholar

    5. Stephen R. Pennington
      View author publications

      You can also search for this author in PubMed Google Scholar

    Corresponding author

    Correspondence to Stephen R. Pennington.

    Additional information

    This article is part of the Topical Collection on Psoriatic Arthritis

    Aisha Q. Butt and Angela McArdle contributed equally to this manuscript.

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Butt, A.Q., McArdle, A., Gibson, D.S. et al. Psoriatic Arthritis Under a Proteomic Spotlight: Application of Novel Technologies to Advance Diagnosis and Management. Curr Rheumatol Rep 17, 35 (2015). https://doi.org/10.1007/s11926-015-0509-0

    Download citation

    • Published:

    • DOI: https://doi.org/10.1007/s11926-015-0509-0

    Keywords

    Search

    Navigation